How to Value a Veterinary Clinic Chain in 2026

I spend a lot of time in veterinary M&A, and the most frequent question I get from multi-location vet group owners is some version of: "My friend sold his single practice for 8x — what's my five-location group worth?" The answer is almost always more than they expect. Multi-location veterinary groups with professional management, geographic clustering, and strong associate retention are among the most sought-after acquisitions in all of healthcare private equity. And the economics of the "second bite of the apple" can be genuinely life-changing.

Let me walk you through how these groups are valued, who's buying them, and what separates a 10x deal from a 16x deal.

The Platform vs. Add-On Valuation Gap

The single most important concept in veterinary group valuation is the distinction between a platform acquisition and an add-on acquisition. This distinction alone can double or triple your valuation.

An add-onis a single practice or small group (1-3 locations) purchased by an existing PE-backed veterinary platform. The platform already has the management team, the back-office infrastructure, the purchasing power, and the IT systems. They're buying your patients and your revenue. Add-ons typically trade at 6-9x EBITDA, sometimes less for single locations in non-strategic markets.

A platformis a multi-location group (typically 5+ locations) that a PE firm acquires as the foundation for a new veterinary network. The PE firm needs your management team, your systems, your geographic footprint, and your growth trajectory as the chassis they'll bolt additional acquisitions onto. Platforms trade at 10-16x EBITDA, with the exact multiple driven by size, growth rate, management depth, and market position.

The math is stark. A 5-location vet group generating $2M in EBITDA might sell for $12-16M as an add-on to Mars/VCA (6-8x) or $20-32M as a platform to a PE firm (10-16x). Same business, potentially double the valuation, entirely dependent on buyer type and positioning.

What Drives a Vet Group to Platform-Level Multiples

Not every multi-location vet group qualifies for platform treatment. I've seen 8-location groups trade at add-on multiples because they lacked the infrastructure PE firms need. Here's what actually matters:

Management depth beyond the founder. This is the number one qualifier. If you're the founder-veterinarian and you're still the de facto CEO, COO, CFO, and lead clinician, your group is not a platform — it's a large practice with satellites. PE firms need a management layer: a practice manager or regional director who can run operations, an office manager at each location, and ideally a non-clinical business person handling growth, HR, and finance. The day-to-day cannot depend on the selling veterinarian.

Geographic clustering. Five locations within a 50-mile radius is dramatically more valuable than five locations scattered across three states. Clustering enables shared resources (relief veterinarians, equipment, marketing), brand recognition, and the ability to refer specialty cases between locations. A clustered group is also a more efficient platform for bolt-on acquisitions because new locations benefit from existing infrastructure immediately.

Associate veterinarian retention. This is the existential risk in every vet deal, and PE firms scrutinize it obsessively. Associate veterinarians are in extreme demand — there are roughly 1.5 open positions for every available vet nationally. If your associates leave post-acquisition, you lose 30-50% of revenue per departing doctor, and replacing them takes 6-12 months. Groups with average associate tenure of 3+ years, competitive compensation (typically 20-25% of production plus benefits), and a culture that associates want to stay in command premium multiples. Groups with high associate turnover get discounted heavily or passed over entirely.

Same-store revenue growth. PE firms want to see 5-10% annual same-store growth across the group. This demonstrates that the practices are healthy and growing organically, not just aggregated. Same-store growth comes from increasing average transaction value (wellness plans, dental procedures, diagnostics), improving visit frequency, and new client acquisition. A group with flat same-store revenue is valued differently than one compounding at 7% annually.

The Named Buyers: Who's Acquiring Vet Groups

Understanding the buyer landscape is critical because each buyer type values different attributes and pays different multiples.

• Mars Veterinary Health (VCA, Banfield, BluePearl): The largest veterinary company in the world with 3,000+ hospitals. Mars pays competitive multiples for strategic acquisitions, particularly in markets where they lack presence. They are the most disciplined buyer — expect thorough diligence and fair-but-not-premium pricing for add-ons.
• NVA (National Veterinary Associates): PE-backed (JAB Holding), 1,400+ hospitals. NVA has historically been one of the most aggressive acquirers and often pays at the top of the add-on range. They emphasize the "NVA model" of local autonomy with corporate support.
• Pathway Vet Alliance: TSG Consumer Partners-backed, 400+ hospitals. Pathway has been an active platform builder in the South and Midwest. They're often competitive on platform acquisitions in their target geographies.
• Thrive Pet Healthcare: 400+ hospitals, formed from the merger of several regional platforms. Thrive is active in both platform and add-on acquisitions with a focus on integrated care.
• Mid-market PE firms: Dozens of PE firms have entered veterinary in the past five years, creating new platforms. These are often the highest-paying buyers for platform acquisitions because they need a management team and infrastructure to deploy their capital.

Running a competitive process with multiple buyer types is how you discover your group's true market value. I've seen platform-quality groups receive offers ranging from 9x to 15x EBITDA from different buyers — a $12M spread on a $2M EBITDA business. Having an advisor who knows these buyers and can create competitive tension is worth their fee many times over.

The "Second Bite" Economics

The most compelling financial structure in veterinary M&A — and the one that sophisticated sellers optimize for — is the "second bite of the apple." Here's how it works, with real numbers:

You own a vet group generating $2M EBITDA. A PE firm offers to buy 70% of the business at 12x EBITDA, valuing the enterprise at $24M. You receive $16.8M in cash (70% of $24M) and retain 30% equity — your "rollover." Your retained equity is valued at $7.2M.

Over the next 4-5 years, the PE firm deploys capital to acquire 15-20 additional practices. The combined platform grows from $2M to $8M in EBITDA through acquisitions, same-store growth, and operational improvements. The PE firm then sells the combined platform to a larger PE firm at 14x EBITDA — an enterprise value of $112M.

Your 30% rollover is now worth $33.6M (30% of $112M). Your "second bite" generated $33.6M on a $7.2M retained stake — a 4.7x return in addition to the $16.8M you already cashed out. Total proceeds: $50.4M on a business that was worth $24M at the first transaction. This is not hypothetical — I've seen these economics play out repeatedly in veterinary, dental, and dermatology roll-ups over the past decade.

The key to maximizing the second bite: stay actively involved in the growth strategy, align your incentives with the PE firm's value creation plan, and negotiate your management equity carefully. The rollover percentage, participation in future equity grants, and governance rights all impact your second-bite economics significantly.

What Kills Vet Group Valuations

Founder dependency. If you're still seeing 40%+ of the patients across all locations, managing every staffing decision, and the associates view you as irreplaceable, your group will be valued as a large practice, not a platform. Start delegating clinical and operational responsibilities 2-3 years before a potential exit.

Real estate entanglement. Many vet group owners also own the real estate. If the clinics occupy buildings you own, the leases need to be at fair market rates with assignable terms. Below-market leases inflate EBITDA artificially, and PE firms will adjust for this. Above-market leases depress EBITDA and hurt your multiple. Get the real estate valued independently and structure arm's-length leases before going to market.

Inconsistent operations across locations. If each location runs different software, has different pricing, uses different clinical protocols, and operates as an independent practice rather than part of a group, the PE firm sees integration work ahead of them — and they discount accordingly. Standardize your PIMS (practice information management system), pricing, and clinical protocols across all locations before engaging buyers.

The Bottom Line

Multi-location veterinary groups are valued at a premium because they solve the PE industry's biggest challenge: deploying capital at scale into a fragmented, growing market. If your group has 5+ locations, management depth, geographic clustering, strong associate retention, and consistent same-store growth, you're in the 10-16x EBITDA range for a platform acquisition. If you're missing one or more of those elements, you're likely in the 6-9x add-on range — still a strong outcome, but meaningfully less. The difference between those two tiers is often $10-20M in enterprise value, which makes the 2-3 year investment in building platform-level infrastructure one of the highest-ROI decisions a veterinary group owner can make.